Replies to post #1700 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Gfp - how confident can Cortex be that the two backup compounds won't show the same cellular modification issues that CX-717 has?

If I heard correctly, Dr. Stoll said the backup compounds have not show the same problem, but isn't it way too early to say that until they go through the same level of tox studies that CX-717 has?

Or does Cortex now know what to look for in early tox data that is a indication of the cellular problem and can thus extrapolate that the backup compounds won't show that problem?... Aiming4.

[Aiming4]

Gfp - if Cortex does decide to permanently stop CX-717 development for ADHD, is there any chance CX-717 would still be pushed forward in AD development (i.e. even beyond the trials that Dr. Stoll mentioned)?

In other words, might CX-717 still be viable for AD development even with the histo issue, since the AD doses will be below the threshold that triggers those cellular changes?

Or would it just be too risky to push CX-717 forward, or perhaps not cost effective since the backup compounds are being brought forward?... Aiming4.

[galexa10]

GFP -- Those CDs are looking pretty good right now!